NCT02395575View on ClinicalTrials.gov

A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

October 31, 2017

Conditions
Breast Cancer
Trial Locations (1)

75005

Institut Curie, Paris

Sponsors
All Listed Sponsors
collaborator

Institut Curie

OTHER

lead

NanoString Technologies, Inc.

INDUSTRY

NCT02395575 - A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay | Biotech Hunter | Biotech Hunter